Theriva Biologics, Inc. Common Stock (TOVX)
Competitors to Theriva Biologics, Inc. Common Stock (TOVX)
Agenus Inc. AGEN -6.71%
Agenus Inc. focuses on immuno-oncology and has developed a pipeline of antibody-based therapies. Both Agenus and Theriva Biologics are pursuing innovative cancer treatments, positioning themselves in the biologics space. However, Agenus has a more established platform and a diverse range of candidates in clinical trials, giving them a competitive advantage in terms of a broader pipeline and better market presence.
Celsion Corporation
Celsion Corporation specializes in developing localized treatments for cancer, similar to Theriva Biologics' focus. However, Celsion's longer history in the market and established relationships give it a competitive edge. While both companies aim to address similar needs within oncology, Celsion's more advanced pipeline enhances its competitive stance against Theriva.
ImmunoGen, Inc.
ImmunoGen is dedicated to developing antibody-drug conjugates for cancer therapy, which gives it a distinct approach compared to Theriva Biologics. Both companies target similar oncological indications, but ImmunoGen's advanced clinical trials and higher visibility in the oncology space offer it competitive leverage, indicating a stronger positioning in the market.
Moderna, Inc. MRNA +4.45%
Moderna, primarily known for its mRNA technology, has ventured into cancer therapeutics, thereby competing with Theriva Biologics in the oncology domain. While Theriva focuses on localized therapies and innovative drug delivery systems, Moderna leverages its extensive research capabilities and financial resources stemming from its success in vaccines to develop a range of cancer therapies, placing it at a more technologically advanced stage.
OncoSec Medical Incorporated
OncoSec Medical operates in the immuno-oncology space, focusing on intratumoral delivery of therapies that share some goals with Theriva Biologics. However, OncoSec has made significant advancements in clinical studies and collaborations within the field of cancer immunotherapy, positioning itself with a slight competitive advantage over Theriva, especially among investors looking for proven clinical data.